People who have no symptoms of Alzheimer’s disease but who have an abnormal protein believed to be a hallmark of the illness should be enrolled in clinical trials to test whether drugs can head off the disease, according to researchers. Reisa Sperling, HMS associate professor of neurology at Brigham and Women’s Hospital, is the lead author.
